Johnson & Johnson (NYSE:JNJ) – Janssen Pleads Guilty to Selling Risperdal Off-Label

[at Bloomberg] – Johnson & Johnson’s Janssen unit pleaded guilty to misbranding its anti-psychotic medication Risperdal. The plea is part of a $2.2 billion settlement with U.S. prosecutors. Read more on this. . . . → Read More: Johnson & Johnson (NYSE:JNJ) – Janssen Pleads Guilty to Selling Risperdal Off-Label Similar posts: Stock Update: Johnson & Johnson (NYSE:JNJ) – Johnson & Johnson to Participate in Credit Suisse 2013 Health Care Conference Stock Update: The Home Depot Inc. (NYSE:HD) – Why trader is selling Home Depot puts Johnson & Johnson (NYSE:JNJ) – Solid Earnings, But Momentum Has Pushed Up Expectations